NASDAQ · SVRA
Savara Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SVRA: Nov 11, 2026
Savara Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.18. The reported EPS for the same quarter last year was $-0.14.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.18 | $-0.15 | $-0.23 | 4 |
| Dec 2026 | $-0.17 | $-0.14 | $-0.24 | 4 |
| Mar 2027 | $-0.17 | $-0.12 | $-0.22 | 2 |
| Jun 2027 | $-0.13 | $-0.08 | $-0.18 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · BNK Invest · Zacks · The Motley Fool- RTTNews · Oct 29, 4:01 AM EDTBiotech Stocks Facing FDA Decision In November 2026(RTTNews) – The FDA's November calendar has more than a dozen PDUFA dates on the horizon, setting the stage for an eventful month in the regulatory landscape.
- BNK Invest · Sep 24, 5:05 PM EDTNotable Thursday Option Activity: SVRA, CAR, SPCXAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Savara Inc (Symbol: SVRA), where a total of 10,285 contracts have traded so far, representing approximately 1.0 million underlying shares. That amounts to about 70.6% of
- Zacks · Jul 22, 9:21 AM EDTHere's Why You Should Add Savara Stock to Your Portfolio NowSVRA advances Molbreevi with positive long-term phase III data, an FDA review on track and expanded patent protection supporting its commercial outlook.
- The Motley Fool · Jun 27, 11:34 AM EDTWhat Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline394,528 shares of Common Stock were sold for about $2.24 million on June 22, 2026, at a weighted average price of around $5.68 per share.
- The Motley Fool · Mar 15, 10:59 AM EDTVR Adviser Adds Over 1 Million Savara SharesVR Adviser Bought 1,059,332 shares of Savara.
- RTTNews · Dec 26, 8:50 AM ESTWeekly Buzz: FDA OKs Roche's Lunsumio VELO; It's No For Tolbrutinib; BioMarin, SNY Open Wallets(RTTNews) – In a holiday-shortened week, the biotech sector saw a wave of FDA approvals, strategic acquisitions, and key clinical trial readouts – alongside several setbacks that shaped the sector's outlook.
- Fintel · Dec 23, 7:02 AM ESTHC Wainwright & Co. Maintains Savara (SVRA) Buy RecommendationFintel reports that on December 23, 2025, HC Wainwright & Co. maintained coverage of Savara (NasdaqGS:SVRA) with a Buy recommendation. Analyst Price Forecast Suggests 62.58% Upside
- RTTNews · Dec 23, 1:45 AM ESTSavara Resubmits BLA For MOLBREEVI In Autoimmune PAP(RTTNews) – Savara Inc. (SVRA) announced that it has resubmitted the Biologics License Application to the FDA for MOLBREEVI, its investigational therapy currently in Phase 3 development, seeking approval for the treatment of autoimmune pulmonary alveolar proteinosis (autoimmune P
- Fintel · Dec 18, 7:02 PM ESTWells Fargo Maintains Savara (SVRA) Overweight RecommendationFintel reports that on December 18, 2025, Wells Fargo maintained coverage of Savara (NasdaqGS:SVRA) with a Overweight recommendation. Analyst Price Forecast Suggests 73.72% Upside
- Fintel · Nov 14, 7:05 PM ESTOppenheimer Maintains Savara (SVRA) Outperform RecommendationFintel reports that on November 14, 2025, Oppenheimer maintained coverage of Savara (NasdaqGS:SVRA) with a Outperform recommendation. Analyst Price Forecast Suggests 144.62% Upside
- Fintel · Nov 13, 7:03 PM ESTCitizens Maintains Savara (SVRA) Market Outperform RecommendationFintel reports that on November 13, 2025, Citizens maintained coverage of Savara (NasdaqGS:SVRA) with a Market Outperform recommendation. Analyst Price Forecast Suggests 146.92% Upside
- Fintel · Oct 23, 8:03 AM EDTJMP Securities Maintains Savara (SVRA) Market Outperform RecommendationFintel reports that on October 23, 2025, JMP Securities maintained coverage of Savara (NasdaqGS:SVRA) with a Market Outperform recommendation. Analyst Price Forecast Suggests 142.86% Upside
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Savara Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.